Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 16/20 | 0.45 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.39 |
| ▸ | DNM2 | P50570 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL853443 | 0.86 | TLR7 (0.45) | TLR7TLR8DHFRDNM2 | |
| SCHEMBL854178 | 0.85 | ALDH1A1 (0.51) | TLR7TLR8DHFR | |
| SCHEMBL3701139 | 0.83 | TLR7 (0.64) | TLR7TLR8 | |
| SCHEMBL853209 | 0.83 | DHFR (0.59) | TLR7TLR8DHFR | |
| SCHEMBL854515 | 0.81 | TLR7 (0.52) | TLR7TLR8 | |
| SCHEMBL19056490 | 0.81 | TLR7 (0.40) | TLR7TLR8MAPT | |
| SCHEMBL853744 | 0.80 | TLR7 (0.46) | TLR7DHFRMAPT | |
| SCHEMBL28873208 | 0.78 | TLR7 (0.55) | TLR7TLR8 | |
| SCHEMBL30036873 | 0.77 | TLR7 (0.56) | TLR7TLR8 | |
| SCHEMBL861166 | 0.77 | TLR7 (0.48) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2432768-A1 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND FURTHER DISEASES | AstraZeneca AB (SE) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010133885-A1 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND FURTHER DISEASES | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | WO | disclosed |